About Synapse differentiation-inducing gene protein 1-like
Synapse differentiation-inducing gene protein 1-like (SYNDIG1L) is a protein
from Homo sapiens identified by UniProt accession
A6NDD5, 238 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Synapse differentiation-inducing gene protein 1-like |
|---|
| UniProt accession | A6NDD5 |
|---|
| Gene | SYNDIG1L |
|---|
| Organism | Homo sapiens |
|---|
| Length | 238 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (24)
Diseases linked to this target (Open Targets).
- mathematical ability · score 0.36
- self reported educational attainment · score 0.34
- neurofibrillary tangles measurement · score 0.29
- cognitive function measurement · score 0.26
- PHF-tau measurement · score 0.25
- vital capacity · score 0.23
- neurodegenerative disease · score 0.15
- forced expiratory volume · score 0.13
- Abnormal central motor function · score 0.09
- type 2 diabetes mellitus · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-A6NDD5-F1 | alphafold | PREDICTED | 55.52 | — |
Amino-acid sequence (238 residues)
MESLSELQNP LLPRSPAHLH GPYPYPETPP SWSCQEKLYS YLLGGAGPAG AHQLLDPGSL QLAVEAWYRP SCLLGRDKVK EPRAGSCETS FTEDREPQEG PPEQPTGPGQ AAENVTIQTV SYGVQEELRD QEDDQEEEES DATSTESESE DNFLTLPPRD HLGLTLFSML CCFWPLGIAA FYFSQGTSKA ISKGDFRLAS TTSRRALFLA TLAIAVGAGL YVAVVVALAA YMSQNGHG
Explore Synapse differentiation-inducing gene protein 1-like with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets